SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Polyrizon Ltd. is a development stage biotech company, which engages in the development of nasal hydrogels. It provides barriers from the interaction of biological assaults, including a new strain of coronavirus, influenza, allergens and other airborne pathogens with the nasal epithelial tissue. The company was founded by Tomer Izraeli in January 2005 and is headquartered in Raanana, Israel.

Polyrizon Ltd.

Polyrizon Ltd. Ordinary Shares

PLRZ is trending due to positive mucoadhesion data for its intranasal Naloxone program, sparking excitement about its potential as a multi-day runner. Community discussions revolve around the significance of the manufacturing milestone and superior data, while some traders are wary of potential dilution given the company's history and low float. The stock is also gaining attention within the context of other low-float Israeli stocks experiencing significant moves.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is trending as the quantum computing sector garners attention, with discussions focusing on its superconducting QPU systems and potential for scalability compared to other quantum computing approaches. Community members debate the company's valuation relative to its revenue and the competitive landscape, while also discussing potential catalysts and trading strategies involving options. Some are optimistic about Rigetti's technology and long-term potential, while others express skepticism, citing concerns about profitability and competition from larger companies.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as traders discuss its potential for institutional adoption and retail activity, specifically meme coins. Community members are analyzing entry points and debating its ability to outperform other cryptos, while some express concern over recent price drops. Bullish sentiment revolves around potential rallies and strong community support.

UP Fintech Holding Ltd. is an online brokerage firm that focuses on global investors. It provides an online trading platform that enables investors to trade in equities and other financial instruments on multiple exchanges around the world. The firm offers products and services, as well as a user experience to customers through its mobile first strategy. The company was founded by Tian Hua Wu in June 2014 and is headquartered in Singapore.

UP Fintech Holding Ltd - ADR

TIGR is trending due to its recent earnings report, which showed record revenue and profit, sparking discussions about its undervaluation relative to competitors like HOOD. The community is highlighting the company's strong growth in global client assets and its potential for significant price appreciation, drawing comparisons to HOOD's earlier run-up.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending amid speculation about a potential acquisition of Warner Bros. Discovery, with many debating whether the deal would be beneficial. Community discussions revolve around potential price targets and technical analysis, while some express concerns about the company's recent performance and programming decisions. The possibility of a bidding war with other major players like Comcast and Paramount Skydance is also fueling the conversation.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

SERV is trending amid speculation and excitement around the robotics sector, driven by potential government support and company-specific developments like overnight trading highs and high trading volumes. Community members are actively discussing potential short squeezes and comparing SERV to other robotics plays, anticipating further gains and focusing on the company's growth prospects with its DoorDash partnership. Some see a buying opportunity, while others are wary, pointing to past volatility and dilution.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath ($PATH) is trending following the release of its Q3 earnings, which beat analyst expectations and showed profitability. The community is actively discussing the company's growth, partnerships, and potential for a continued uptrend, while also debating its valuation relative to peers and the impact of short positions.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE is trending as the community rallies around the revival of OG memes on the Solana blockchain. Community members emphasize consistent engagement and building a strong culture, expressing conviction that $RAGE represents more than just a coin. Discussions highlight the importance of community over charts, with members actively working towards broader recognition and adoption.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum Inc. is trending as investors react to the company's announcement of a new U.S. Government Business Unit and recent analyst coverage with an outperform rating. Community discussions revolve around potential government contracts and the company's prospects within the quantum computing sector.  Despite being unprofitable, some investors are drawn to QBTS as a pure-laser computing play and a potential beneficiary of growing AI energy demands.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MLTX is trending amid mixed sentiment following recent trial setbacks and shareholder lawsuits, though analysts see potential upside and key readouts are expected in the coming quarters. Community members are weighing the risks against the potential for a buyout, drawing comparisons to other biotech successes, and closely watching the upcoming FDA meeting for clarity. Discussions also focus on technical analyses, potential market size, and institutional investment activity.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Protara Therapeutics, Inc. (NASDAQ:TARA) Given Average Rating of "Moderate Buy" by Analysts

Shares of Protara Therapeutics, Inc. (NASDAQ:TARA - Get Free Report) have received an average recommendation of "Moderate Buy" from the seven analysts that are presently covering the firm, MarketBeat...

HC Wainwright Reaffirms "Buy" Rating for Protara Therapeutics (NASDAQ:TARA)

HC Wainwright reiterated a "buy" rating and set a $23.00 price objective on shares of Protara Therapeutics in a research note on Wednesday...

What's Going On With Protara Therapeutics Stock Wednesday?

TARA-002, a cell-based therapy by Protara Therapeutics, shows promising results in treating lymphatic malformations in pediatric patients.read more...

Lifesci Capital Issues Optimistic Forecast for TARA Earnings

Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) - Equities researchers at Lifesci Capital lifted their FY2025 EPS estimates for Protara Therapeutics in a report released on Monday, November...

Cantor Fitzgerald Issues Positive Outlook for TARA Earnings

Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) - Research analysts at Cantor Fitzgerald lifted their FY2025 EPS estimates for shares of Protara Therapeutics in a report released on Tuesday...

Q4 EPS Estimate for Protara Therapeutics Boosted by Analyst

Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) - Investment analysts at HC Wainwright upped their Q4 2025 earnings per share (EPS) estimates for Protara Therapeutics in a research note issued...

Protara Therapeutics (NASDAQ:TARA) Announces Earnings Results

Protara Therapeutics (NASDAQ:TARA - Get Free Report) announced its earnings results on Monday. The company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of...

Shares of Protara Therapeutics Inc. skyrocketed over 100% on Thursday afternoon, reaching levels last seen in January 2022 amid a trading volume over 540 times the daily average.The clinical-stage company unveiled promising results from its ongoing Phase 2 ADVANCED-2 trial for its investigational cell-based therapy, TARA-002.The trial evaluates TARA-002 for high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) in patients with carcinoma in situ (CIS) who are either Bacillus Calmette-Guérin (BCG)-Unresponsive or BCG-Naive. Highlights from the study include:• A complete response (CR) rate of 72% at six months and 70% at any time during the trial.• 100% of patients with CR at three months maintained it through six months.• Two out of three patients maintained a CR at nine months.Adverse events were generally mild, with no discontinuations due to treatment-related side effects. The most common issues, such as flu-like symptoms or bladder irritation, were consistent with responses to bacterial immunotherapy and typically resolved within hours or days.The data will be presented during a poster session at the 25th Annual Meeting of the Society of Urologic Oncology in Dallas, Texas, the company said."We are thrilled with these positive six-month data, which reinforce TARA-002's potential in NMIBC, while offering a compelling product profile for physicians and patients," said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics.&nbsp;"We believe these encouraging data together with our international site expansion will accelerate patient enrollment, and we look forward to reporting initial data from 12-month evaluable patients in mid-2025."<figure class="image"><img style="aspect-ratio:1318/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_05_at_11_12_34_PM_c755be6fcf.png" alt="Screenshot 2024-12-05 at 11.12.34 PM.png" width="1318" height="318"><figcaption>TARA sentiment and message volume on Dec 5 as of 12:30 am ET | source: Stocktwits</figcaption></figure>Retail sentiment for TARA turned ‘extremely bullish’ on Stocktwits, with the ticker trending in the top 10 symbols by Thursday afternoon.&nbsp;<stembedurl>https://stocktwits.com/eXpeditor/message/595247480</stembedurl>Retail chatter on the stock has increased by 2,100% over the past year, with follower count growing by nearly 4%.Protara shares have surged almost 230% year-to-date, significantly outperforming broader market indices.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail chatter on Protara has increased by 2,100% over the past year, with follower count growing by nearly 4%.

Protara Therapeutics Stock Doubles On Promising Bladder Cancer Trial Data: Retail Buzz Spikes

The data will be presented during a poster session at the 25th Annual Meeting of the Society of Urologic Oncology in Dallas, Texas, the company said.

Equity

The data will be presented during a poster session at the 25th Annual Meeting of the Society of Urologic Oncology in Dallas, Texas, the company said.


12 titres de soins de sant  en mouvement lors de la pr -ouverture le 05/04/2024

Gagnants
Le titre Etao International Co (NASDAQ:ETAO) a mont vendredi de 25,61% 3,58 dollars lors de la session pre-market.
Le titre Protara Therapeutics (NASDAQ:TARA) a augment de 21,39% 4,88...

Protara Therapeutics announces $45M private placement financing

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman and Jacqueline Zummo in March 2006 and is headquartered in New York, NY.

TARA
Protara Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest TARA News

TARAProtara Therapeutics Inc